Endoscopically inserted nasobiliary catheters for high dose-rate brachytherapy as part of neoadjuvant therapy for perihilar cholangiocarcinoma

Background and aim: Selected patients with unresectable perihilar cholangiocarcinoma can undergo neoadjuvant chemoradiotherapy followed by liver transplantation, which has been shown to improve survival. The aim of this study was to determine the feasibility and safety of endoscopic transpapillary insertion of nasobiliary tubes (NBTs) and brachytherapy catheters for high dose-rate (HDR) brachytherapy as part of this neoadjuvant chemoradiotherapy.

Patients and methods: Medical records of patients undergoing biliary brachytherapy for hilar cholangiocarcinoma at the Mayo Clinic, Rochester were reviewed. Patients were treated with curative intent using external beam radiotherapy (4500 cGy), chemotherapy (5-FU or capecitabine), and HDR brachytherapy (930 – 1600 cGy in one to four fractions delivered over 1 – 2 days) prior to planned liver transplantation.

Results: Between 2009 and 2013, 40 patients underwent biliary HDR brachytherapy via endoscopically placed NBTs (8.5 – 10 Fr). Patients had a median age of 55 years (range 28 – 68); 25 patients (62.5 %) had primary sclerosing cholangitis. Prior to therapy, 29 patients (72.5 %) had plastic stents, two (5 %) had metal stents, and nine (22.5 %) had no stents. Bilateral NBTs were placed in five patients (12.5 %). NBT/brachytherapy catheter displacement was seen in eight patients (20 %) – five intraprocedure and three post-procedure. A radiotherapy error and NBT kinking each occurred once. Post-procedure adverse events included: cholangitis (n = 5; 12.5 %), severe abdominal pain (n = 3; 7.5 %), duodenopathy (n = 3; 7.5 %), gastropathy (n = 3; 7.5 %), and both duodenopathy and gastropathy (n = 2; 5 %).

Conclusion: HDR biliary brachytherapy administered via endoscopically placed NBTs and brachytherapy catheters is technically feasible and appears reasonably safe in selected patients with unresectable perihilar cholangiocarcinoma.

• References

• 1 Blechacz B, Komuta M, Roskams T et al. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011; 8: 512-522
• 2 DeOliveira ML, Cunningham SC, Cameron JL et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245: 755-762
• 3 Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology 2009; 136: 1134-1144
• 4 Jarnagin WR, Fong Y, DeMatteo RP et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234: 507-517 discussion 517-509
• 5 Kosuge T, Yamamoto J, Shimada K et al. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999; 230: 663-671
• 6 Pichlmayr R, Weimann A, Klempnauer J et al. Surgical treatment in proximal bile duct cancer. A single-center experience. . Ann Surg 1996; 224: 628-638
• 7 Heimbach JK, Gores GJ, Haddock MG et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis 2004; 24: 201-207
• 8 Darwish MuradS, Kim WR, Harnois DM et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143: 88-98 (quiz e14, e83)
• 9 Gores GJ, Gish RG, Sudan D et al. Model for end-stage liver disease (MELD) exception for cholangiocarcinoma or biliary dysplasia. Liver Transpl 2006; 12: 95-S97
• 10 Simmons DT, Baron TH, Petersen BT et al. A novel endoscopic approach to brachytherapy in the management of hilar cholangiocarcinoma. Am J Gastroenterol 2006; 101: 1792-1796
• 11 Baron TH, Harewood GC, Rumalla A et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol 2004; 2: 214-219
• 12 Kipp BR, Stadheim LM, Halling SA et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 2004; 99: 1675-1681
• 13 Kubo HD, Glasgow GP, Pethel TD et al. High dose-rate brachytherapy treatment delivery: report of the AAPM Radiation Therapy Committee Task Group No. 59. . Med Phys 1998; 25: 375-403
• 14 Fletcher MS, Brinkley D, Dawson JL et al. Treatment of high bileduct carcinoma by internal radiotherapy with iridium-192 wire. Lancet 1981; 2: 172-174
• 15 Bowling TE, Galbraith SM, Hatfield AR et al. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 1996; 39: 852-855
• 16 Bruha R, Petrtyl J, Kubecova M et al. Intraluminal brachytherapy and selfexpandable stents in nonresectable biliary malignancies—the question of long-term palliation. Hepatogastroenterology 2001; 48: 631-637
• 17 Foo ML, Gunderson LL, Bender CE et al. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 1997; 39: 929-935
• 18 Gerhards MF, van Gulik TM, Gonzalez GonzalezD et al. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 2003; 27: 173-179
• 19 Chen Y, Wang XL, Yan ZP et al. HDR-192Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice. World J Gastroenterol 2004; 10: 3506-3510
• 20 Eschelman DJ, Shapiro MJ, Bonn J et al. Malignant biliary duct obstruction: long-term experience with Gianturco stents and combined-modality radiation therapy. Radiology 1996; 200: 717-724
• 21 Kamada T, Saitou H, Takamura A et al. The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys 1996; 34: 767-774
• 22 Valek V, Kysela P, Kala Z et al. Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: a prospective randomised study. Eur J Radiol 2007; 62: 175-179
• 23 Andrasina T, Valek V, Panek J et al. Multimodal oncological therapy comprising stents, brachytherapy, and regional chemotherapy for cholangiocarcinoma. Gut Liver 2010; 4: 82-S88
• 24 Haffty BG, Mate TP, Greenwood LH et al. Malignant biliary obstruction: intracavitary treatment with a high-dose-rate remote afterloading device. Radiology 1987; 164: 574-576
• 25 Lu JJ, Bains YS, Abdel-Wahab M et al. High-dose-rate remote afterloading intracavitary brachytherapy for the treatment of extrahepatic biliary duct carcinoma. Cancer J 2002; 8: 74-78
• 26 Nakamura R, Kato K, Sone M et al. Duodenal complications in radiotherapy for bile duct cancer: a dose-volume histogram analysis. Brachytherapy 2010; 9: 71-75
• 27 Shin HS, Seong J, Kim WC et al. Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts. Int J Radiat Oncol Biol Phys 2003; 57: 105-112
• 28 Dvorak J, Petera J, Papik Z et al. Transduodenal intraluminal high dose rate brachytherapy in the treatment of carcinomas of the subhepatic region. Hepatogastroenterology 2002; 49: 1045-1047
• 29 Urban MS, Siegel JH, Pavlou W et al. Treatment of malignant biliary obstruction with a high-dose rate remote afterloading device using a 10 F nasobiliary tube. Gastrointest Endosc 1990; 36: 292-296